Sodium oxybate ER is a Small Molecule owned by Avadel Pharmaceuticals, and is involved in 8 clinical trials, of which 7 were completed, and 1 is ongoing.

Sodium oxybate agonizes GABAB receptor function. GABA is the major inhibitory neurotransmitter in the brain. Its production, release, re-uptake and metabolism occur in the nervous system. The GABA transmitter interacts with two major types of receptors, ionotropic GABAA and the metabotropic GABAB receptors. The drug candidate works by mimicking the activity of natural gamma-hydroxybutyrate (GHB). It binds and activates the GABA-B receptors in a manner similar to natural GHB. Thus, drug candidate enhances the effect of natural GHB in patients and helps them to fall asleep.

The revenue for Sodium oxybate ER is expected to reach a total of $3.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sodium oxybate ER NPV Report.

Sodium oxybate ER is currently owned by Avadel Pharmaceuticals.

Sodium oxybate ER Overview

Sodium oxybate (Lumryz) is a central nervous depressant. It is formulated as extended release solution for oral administration. sodium oxybate for is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

Sodium oxybate is under development for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy. The drug candidate is administered orally. The drug candidate is formulated as extended release suspension. It acts by targeting (gamma-aminohydroxybutyric acid-B) GABAB receptor. The development of the drug candidate is based on Micropump platform technology.

Avadel Pharmaceuticals Overview

Avadel Pharmaceuticals (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump – derived platform for liquid oral products, and Medusa that enables controlled release of injectables. It sells products in the US and Ireland. The company operates in St. Louis, Missouri and Charlotte in the US. Avadel is headquartered in Dublin, Ireland.

The operating loss of the company was US$85.6 million in FY2021, compared to an operating profit of US$5.8 million in FY2020. The net loss of the company was US$77.3 million in FY2021, compared to a net profit of US$7 million in FY2020.

Quick View – Sodium oxybate ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Sodium oxybate ER
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Archived (Marketed)

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.